What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2024-05-13 compared with 2023-11-09 · 72 added, 72 removed, 10 unchanged (94% of the section changed)

Other Information

Placement Agent Agreement, dated September 28, 2023, among Tonix Pharmaceuticals Holding Corp., A.G.P./Alliance

Global Partners and Brookline Capital Markets, a division of Arcadia Securities, LLC, filed as an exhibit to the Current Report

on Form 8-K, filed with the Securities and Exchange Commission (the “Commission”) on September 29, 2023 and incorporated

herein by reference

Merger between Tamandare Explorations Inc.

of Incorporation, filed as an exhibit to the Registration Statement on Form S-1, filed with the Securities and Exchange Commission

(the “Commission”) on April 9, 2008 and incorporated herein by reference.

of Merger between Tamandare Explorations Inc.

and Tonix Pharmaceuticals Holding Corp., effective October 11, 2011, filed as an exhibit

to the Current Report on Form 8-K, filed with the Commission on October 17, 2011 and incorporated herein by reference.

Articles of Incorporation, filed as an exhibit to the Registration Statement on Form S-1, filed with the

Commission on April 9, 2008 and incorporated herein by reference.

Amended and Restated Bylaws, filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on June 3, 2016 and incorporated

herein by reference.

Certificate of Change of

Tonix Pharmaceuticals Holding Corp., dated March 13, 2017 and effective March 17, 2017, filed as an exhibit to the Current Report

on Form 8-K, filed with the Commission on March 16, 2017 and incorporated herein by reference.

Certificate of Amendment to Tonix Pharmaceuticals Holding Corp.’s Articles of Incorporation, effective

June 16, 2017, filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on June 16, 2017 and incorporated

herein by reference.

Specimen Common Stock Certificate,

filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on May 24, 2018 and incorporated herein by reference.

Certificate of Amendment to Tonix Pharmaceuticals Holding Corp.’s Articles of Incorporation, effective

February 10, 2022, filed as an exhibit to the Current Report on Form 8-K filed with the Commission on February 10, 2022 and incorporated

herein by reference.

Certificate of Amendment to Tonix Pharmaceuticals Holding Corp.’s Articles of Incorporation, as

amended, May 17, 2022, filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on May 16, 2022 and incorporated

herein by reference.

Certificate of Amendment to Tonix Pharmaceuticals Holding Corp.’s Articles of Incorporation, effective

December 13, 2022, filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on December 13, 2022 and incorporated

herein by reference.

Certificate of Amendment to Tonix Pharmaceuticals Holding Corp.’s Articles of Incorporation, as

amended, filed with the Commission on May 9, 2023 and incorporated herein by reference.

Amended and Restated Bylaws, filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on June 3, 2016 and

incorporated herein by reference.

of Change of Tonix Pharmaceuticals Holding Corp., dated March 13, 2017 and effective March 17, 2017, filed as an exhibit to the Current

Report on Form 8-K, filed with the Commission on March 16, 2017 and incorporated herein by reference.

of Amendment to Articles of Incorporation, effective June 16, 2017, filed as an exhibit to the Current Report on Form 8-K, filed

with the Commission on June 16, 2017 and incorporated herein by reference.

of Amendment to Tonix Pharmaceuticals Holding Corp.’s Articles of Incorporation, as amended, filed with the Secretary of State

of the State of Nevada on May 3, 2019.

Certificate of Amendment

to Tonix Pharmaceuticals Holding Corp.’s Articles of Incorporation, filed as an exhibit to the Current Report on Form 8-K,

filed with the Commission on May 16, 2022 and incorporated herein by reference.

Specimen Common Stock Certificate

1 unchanged sentence

herein by reference.

Description of Registrant’s

Securities, filed as an exhibit to the Annual Report on Form 10-K, filed with the Commission on March 14, 2022 and incorporated herein

by reference.

Form of Common Warrant, filed as an exhibit

to the Current Report on Form 8-K, filed with the Commission on July 28, 2023 and incorporated herein by reference.

Form of Pre-Funded Warrant, filed as an

exhibit to the Current Report on Form 8-K, filed with the Commission on July 28, 2023 and incorporated herein by reference.

Form of Pre-Funded Warrant, filed

as an exhibit to the Current Report on Form 8-K, filed with the Commission on September 29, 2023 and incorporated herein by reference.

Form of Series A Warrant, filed as an exhibit to the Current

Report on Form 8-K, filed with the Commission on September 29, 2023 and incorporated herein by reference.

Form of Series B Warrant, filed

as an exhibit to the Current Report on Form 8-K, filed with the Commission on September 29, 2023 and incorporated herein by reference.

Form of Securities Purchase

Agreement, filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on July 28, 2023 and incorporated

Form of Warrant, filed

as an exhibit to the Registration Statement on Form S-1, filed with the Commission on November 14, 2019 and incorporated herein by

Form of Warrant Agency

Agreement, filed as an exhibit to the Registration Statement on Form S-1, filed with the Commission on November 14, 2019 and incorporated

herein by reference.

Form of Securities Purchase Agreement, dated September 28, 2023, among Tonix Pharmaceuticals Holding Corp.

and the purchasers named therein, , filed as an exhibit to the Current Report on Form 8-K, filed with the Commission on September 29, 2023 and incorporated herein by reference.

Certification of Chief

Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley

Act of 2002.*

Certification of Chief

Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley

Act of 2002.*

Certification of Chief

Executive Officer and Chief Financial Officer pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley

Act of 2002.**

XBRL Instance Document*

XBRL Taxonomy Extension

Schema Document*

XBRL Taxonomy Calculation Linkbase

XBRL Taxonomy Labels Linkbase Document*

XBRL Taxonomy Presentation Linkbase Document*

Cover Page Interactive Data File (formatted as inline

XBRL and contained in Exhibit 101)*

Form of Warrant, filed

as an exhibit to the Registration Statement on Form S-1, filed with the Commission on February 6, 2020 and incorporated herein by

Form of Warrant Agency

Agreement, filed as an exhibit to the Registration Statement on Form S-1, filed with the Commission on February 6, 2020 and incorporated

herein by reference.

Form of Pre-Funded Warrant, filed as an exhibit to

the Current Report on Form 8-K, filed with the Commission on July 18, 2023 and incorporated herein by reference.

Form of Common Warrant, filed as an exhibit to the

Current Report on Form 8-K, filed with the Commission on July 28, 2023 and incorporated herein by reference.

Form of Pre-Funded Warrant, filed as an exhibit to

the Current Report on Form 8-K, filed with the Commission on September 29, 2023, and incorporated herein by reference.

Form of Series A Warrant, filed as an exhibit to the

Current Report on Form 8-K, filed with the Commission on September 29, 2023, and incorporated herein by reference.

Form of Series B Warrant, filed as an exhibit to the

Current Report on Form 8-K, filed with the Commission on September 29, 2023, and incorporated herein by reference.

Form of Pre-Funded Warrant.

filed as an exhibit to

the Current Report on Form 8-K, filed with the Commission on December 21, 2023 and incorporated herein by reference.

Form of Series C Warrant.

filed as an exhibit to the

Current Report on Form 8-K, filed with the Commission on December 21, 2023 and incorporated herein by reference.

Form of Series D Warrant.

filed as an exhibit to the

Current Report on Form 8-K, filed with the Commission on December 21, 2023 and incorporated herein by reference.

Form of Pre-Funded Warrant.

filed as an exhibit to

the Current Report on Form 8-K, filed with the Commission on March 29, 2024, and incorporated herein by reference.

Form of Series E Warrant.

filed as an exhibit to the

Current Report on Form 8-K, filed with the Commission on March 29, 2024, and incorporated herein by reference.

Form of Securities Purchase Agreement.

exhibit to the Current Report on Form 8-K, filed with the Commission on March 29, 2024, and incorporated herein by reference.

Form of Warrant Amendment Agreement.

filed as an exhibit

to the Current Report on Form 8-K, filed with the Commission on March 29, 2024, and incorporated herein by reference.

Placement Agent Agreement dated March 28, 2024,

between Tonix Pharmaceuticals Holding Corp.

and A.G.P./Alliance Global Partners, filed as an exhibit to the Current Report on Form

8-K, filed with the Commission on March 29, 2024, and incorporated herein by reference.

Certification of Chief Executive Officer pursuant to

Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

Certification of Chief Financial Officer pursuant to

Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

Certifications of Chief Executive Officer and Chief

Financial Officer pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,

filed herewith.

** Furnished, not filed.

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned thereunto duly authorized.

TONIX PHARMACEUTICALS HOLDING CORP.

November 9, 2023

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf

by the undersigned thereunto duly authorized.

TONIX PHARMACEUTICALS HOLDING

SETH LEDERMAN

Chief Executive Officer (Principal Executive Officer)

November 9, 2023

Seth Lederman

Chief Executive Officer (Principal Executive

BRADLEY SAENGER

Chief Financial Officer (Principal Financial Officer

and Principal Accounting Officer)

Bradley Saenger

Financial Officer (Principal Financial Officer

Principal Accounting Officer)

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information